Clinical trial

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

NCT06738303

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-07-14

PhasePHASE2

Study timeline

Study start (actual)2025-07-14Date precision: day

Registry last updated2026-10-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Prostate Cancerunresolved

Metastatic Castration-resistant Prostate Cancerunresolved

Interventions

Cabazitaxel and carboplatinDRUG

Lu-PSMA-617DRUG

Sponsors & collaborators

Case Comprehensive Cancer Centerlead sponsor

Mapped research locations

ClevelandOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06738303 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.